Abstract
This post hoc analysis investigated the proportion of patients with moderate-to-severe atopic dermatitis (AD) who achieved clinically-meaningful responses in ≥1 of the signs, symptoms, or quality of life (QoL) domains of AD, despite not achieving an Investigator’s Global Assessment (IGA) score of 0/1. Data from three phase 3 clinical trials (SOLO 1/2 [adults]: NCT02277743/NCT02277769; ADOL [adolescents]: NCT03054428) were utilized. SOLO patients received 300mg dupilumab weekly (qw)/every 2 weeks (q2w), or placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
